Literature DB >> 17693898

Effects of dietary equol administration on the mammary gland in ovariectomized Sprague-Dawley rats.

Dominik Rachoń1, Anne Menche, Tina Vortherms, Dana Seidlová-Wuttke, Wolfgang Wuttke.   

Abstract

OBJECTIVE: To evaluate the effects of dietary equol, a metabolite of soy-derived daidzein or formononetin present in red clover, on the mammary gland of ovariectomized Sprague-Dawley rats.
DESIGN: Sixty ovariectomized rats were divided into five groups (n = 12) and fed soy-free chow with the addition of equol (50 mg/kg chow and 400 mg/kg chow) or estradiol-3 benzoate (E2B) (4.3 mg/kg chow and 17.3 mg/kg chow). The control group received soy-free chow only. After 3 months animals were killed, blood was collected, and the mammary glands were removed for histological and immunohistochemical evaluation.
RESULTS: Equol and E2B treatment significantly increased serum equol and 17beta-estradiol concentrations, respectively. Serum prolactin in animals treated with high-dose equol was also significantly higher than in the controls. Animals treated with high-dose equol had a significantly higher number of terminal ducts and type II lobules compared with controls. This was also apparent in animals treated with low- and high-dose E2B, but a higher number of type I lobules also was seen. Compared with controls, animals treated with high-dose equol had a significantly higher percentage of proliferating cell nuclear antigen-positive cells in terminal ducts and type II lobules. The percentage of progesterone receptor-positive cells in animals treated with high-dose equol was significantly higher only in type II lobules. In animals treated with low- and high-dose E2B, the percentage of proliferating cell nuclear antigen- and progesterone receptor-positive cells was significantly higher in all the mammary structures. Low-dose equol did not have any effects on the parameters listed above.
CONCLUSIONS: High-dose dietary equol administration to ovariectomized rats exerts clear mammotropic effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17693898     DOI: 10.1097/gme.0b013e318093df58

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  7 in total

1.  Equol, via dietary sources or intestinal production, may ameliorate estrogen deficiency-induced bone loss.

Authors:  Connie M Weaver; Leecole L Legette
Journal:  J Nutr       Date:  2010-05-26       Impact factor: 4.798

2.  Supplemental dietary racemic equol has modest benefits to bone but has mild uterotropic activity in ovariectomized rats.

Authors:  Leecole L Legette; Berdine R Martin; Mohammad Shahnazari; Wang-Hee Lee; William G Helferich; Junqi Qian; David J Waters; Alireza Arabshahi; Stephen Barnes; Jo Welch; David G Bostwick; Connie M Weaver
Journal:  J Nutr       Date:  2009-08-26       Impact factor: 4.798

3.  Daidzein-estrogen interaction in the rat uterus and its effect on human breast cancer cell growth.

Authors:  Leonardo Gaete; Andrei N Tchernitchin; Rodrigo Bustamante; Joan Villena; Igor Lemus; Manuel Gidekel; Gustavo Cabrera; Paola Astorga
Journal:  J Med Food       Date:  2012-12-10       Impact factor: 2.786

Review 4.  Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.

Authors:  Il-Sup Kim
Journal:  Antioxidants (Basel)       Date:  2021-06-30

5.  Isoflavone Supplements for Menopausal Women: A Systematic Review.

Authors:  Li-Ru Chen; Nai-Yu Ko; Kuo-Hu Chen
Journal:  Nutrients       Date:  2019-11-04       Impact factor: 5.717

6.  Developmental and Reproductive Effects of SE5-OH: An Equol-Rich Soy-Based Ingredient.

Authors:  Ray A Matulka; Ikuo Matsuura; Tohru Uesugi; Tomomi Ueno; George Burdock
Journal:  J Toxicol       Date:  2008-12-15

7.  Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis.

Authors:  Ilona Kaczmarczyk-Sedlak; Weronika Wojnar; Maria Zych; Ewa Ozimina-Kamińska; Joanna Taranowicz; Agata Siwek
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-12       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.